Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23367161 | 0.89 | — | — | |
| Cyclopentene SCHEMBL9743127 | 0.85 | EPHX2 (0.36) | EPHX2EPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL12093025 | 0.81 | EPHX2 (0.58) | EPHX2EPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL28007009 | 0.81 | EPHX2 (0.32) | EPHX2EPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL12093024 | 0.81 | EPHX2 (0.33) | EPHX2EPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL4454419 | 0.80 | EPHX2 (0.43) | EPHX2EPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL14313766 | 0.78 | GRIN2D (0.50) | EPHX2EPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL25509287 | 0.77 | GRIN2D (0.32) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12943286 | 0.77 | PKM (0.42) | EPHX2EPHX1ALDH1A1 | |
| SCHEMBL4385378 | 0.77 | TSHR (0.53) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118561899-A | Adamantane formamide piperazine axial substituted silicon phthalocyanine and preparation method and application thereof | 福建师范大学 | 2024-08-30 | — | — | CN | claimed |
| CN-117177979-A | Cyclic dibenzyl tetrahydroisoquinoline compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2023-12-05 | — | — | CN | claimed |
| CN-116253740-A | Cyclic dibenzyl isoquinoline compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-13 | — | — | CN | claimed |
| CN-114375293-A | Isoquinoline compounds and preparation method and application thereof | 中国科学院上海药物研究所 | 2022-04-19 | — | — | CN | claimed |
| CN-109836349-B | Adamantane-containing Gemini surfactant and synthesis method thereof | 贺州学院 | 2022-02-15 | — | — | CN | claimed |
| EP-3743061-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | Pascal Biosciences Inc. (CA) | 2020-12-02 | — | — | EP | claimed |
| CN-111518095-A | Azaindole derivatives, and preparation method and application thereof | 华东师范大学 | 2020-08-11 | — | — | CN | claimed |
| WO-2019144126-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | PASCAL BIOSCIENCES INC. (CA) | 2019-07-25 | — | — | WO | claimed |
| CN-109836349-A | A kind of Gemini surface active and its synthetic method containing adamantane | 贺州学院 | 2019-06-04 | — | — | CN | claimed |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-03-14 | — | — | US | claimed |
| US-5543406-A | TREATING ANDROGEN RESPONSIVE OR MEDIATED DISEASE | GLAXO WELLCOME, INC. (US) | 1996-08-06 | — | — | US | claimed |
| EP-0705835-A1 | Quinoxalic-2,3-diones with an oxa or thiaheterocyclic fused ring | CIBA-GEIGY AG (CH) | 1996-04-10 | — | — | EP | claimed |
| EP-0705834-A1 | Quinoxaline-2,3-diones with an azaheterocyclic fused ring | CIBA-GEIGY AG (CH) | 1996-04-10 | — | — | EP | claimed |
| EP-0675901-A1 | DIFLUORO-PENTAPEPTIDE DERIVATIVE ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1995-10-11 | — | — | EP | claimed |
| EP-0641356-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO WELLCOME INC. (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1994014842-A1 | DIFLUORO-PENTAPEPTIDE DERIVATIVE ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1994-07-07 | — | — | WO | claimed |
| WO-1993013124-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO INC. (US) | 1993-07-08 | — | — | WO | claimed |
| EP-0034326-B1 | CHIRAL POLYSILOXANES, PROCESS FOR THEIR PREPARATION AND THEIR USE | Bayer, Ernst, Prof. Dr. (DE) | 1984-07-25 | — | — | EP | claimed |
| US-4387206-A | CHROMATOGRAPHY | BAYER ERNST (DE) | 1983-06-07 | — | — | US | claimed |
| US-4218457-A | ANTICANCER ACTIVITY AND IMMUNOSTIMULATING ACTIVITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1E | EPHX2 4448/4885EPHX1 4832/4885GRIN2D 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.